who is gordon findlay

Gordon Findlay is identified in multiple news outlets as a high-ranking executive at Novo Nordisk, with coverage noting him as the Global Brand Director for Novo Nordisk around 2023–2025. Reports describe his role as overseeing global marketing, product planning, and recovery efforts for GLP-1 therapies such as Norditropin in connection with supply or market initiatives. Several articles from late 2025 also mention an incident in which he reportedly fainted during a White House Oval Office event related to a drug pricing announcement, though Novo Nordisk and other outlets disagree on the specifics of his presence at the meeting. For precise biographical details (education, current title, and location) and to confirm the latest status, checking corporate bios or recent press releases from Novo Nordisk and reputable business news outlets is recommended.